{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:38:14Z","timestamp":1789814294662,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","award":["CAIN457A2232T"],"award-info":[{"award-number":["CAIN457A2232T"]}],"id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Juvenile idiopathic arthritis (JIA)-associated uveitis and chronic anterior uveitis in children may result in permanent sight loss. Currently, the only licensed and approved treatment for JIA-uveitis is adalimumab. However, even in patients where adalimumab may be initially effective, therapeutic response may subside for example, due to neutralising drug antibodies. Further treatment options are necessary to prevent sight loss in children with uveitis. Interleukin 17 is elevated in uveitis. Inhibition of interleukin 17 ameliorates inflammation in mouse models of uveitis. Secukinumab, an antibody which neutralizes interleukin 17\u00a0A, has been shown to be partially effective in adult uveitis. The objective of the Bayesian consensus meeting was to quantify prior expert opinion about the potential utility of secukinumab in treatment of uveitis in JIA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Nine international experts in paediatric rheumatology, paediatric ophthalmology and\/or paediatric uveitis took part in a structured Bayesian prior elicitation meeting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The final consensus was that adalimumab is expected to yield a higher response rate than secukinumab (mean 0.67 vs. 0.55). The uncertainty in the response rate on secukinumab is somewhat larger than for adalimumab. The equivalent sample size for the prior distribution of adalimumab is 15.7 and 13.1 for secukinumab. The decisions based on the combined evidence would still be driven by the trial data, yet substantial enhancement of the power of the study can be expected by adding information from the equivalent of almost 30 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The Bayesian analysis adds substantial enhancement of the power of the study and supports a head-to-head trial of adalimumab and secukinumab for JIA-associated uveitis and chronic anterior uveitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ISRCTN 12,427,150 Registration date 14\/02\/2023. EudraCT 2022-003068-26 Registration date 07\/09\/2022.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12969-025-01107-1","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:54:26Z","timestamp":1747666466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis"],"prefix":"10.1186","volume":"23","author":[{"given":"Athimalaipet V","family":"Ramanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley P","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balini","family":"Balasubramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coziana","family":"Ciurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Foeldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke O","family":"Kreps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu P","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"1107_CR1","doi-asserted-by":"crossref","unstructured":"Kautiained H, Karma A, Aho K. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Kotaniemi K. Volume 108. Ophthalmology; 2001. 2071-5, s.l.","DOI":"10.1016\/S0161-6420(01)00773-4"},{"key":"1107_CR2","doi-asserted-by":"crossref","unstructured":"Prevalence., risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED. 56:647\u2013\u200957, s.l.: Arthritis Rheum, 2007.","DOI":"10.1002\/art.22381"},{"key":"1107_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ajo.2008.11.009","volume":"147","author":"GN Denove","year":"2009","unstructured":"Denove GN, Yu CS. Chronic anterior uveitis in children: clinical characteristics and. Holland. Am J Ophthalmol. F. 2009;147:667\u201378. s.l.","journal-title":"Am J Ophthalmol"},{"key":"1107_CR4","doi-asserted-by":"crossref","unstructured":"Thorne F, Jabs JE, Kedhar DA, Dunn SR. JP. 143:647\u2013\u200955, s.l.: Am J Ophthalmol, 2007.","DOI":"10.1016\/j.ajo.2006.11.025"},{"key":"1107_CR5","unstructured":"Lee C, Bentley V, Kanski CR, Graham JJ. EM. 86:51\u2013\u20096, s.l.: Br J Ophthalmol, 2002."},{"key":"1107_CR6","unstructured":"van der Helders NJ. PJ. CD003129, s.l.: Cochrane Database Syst Rev, 2001."},{"issue":"144\u2013150","key":"1107_CR7","first-page":"sl","volume":"94","author":"MW Beresford","year":"2009","unstructured":"Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis\u20131: Non-biological therapy. Arch Dis Child Ed Pract. 2009;94(144\u2013150):sl.","journal-title":"Arch Dis Child Ed Pract"},{"key":"1107_CR8","unstructured":"Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. Foeldvari I, Wierk A. 32:362\u2013365, s.l.: J Rheumatol, 2005."},{"key":"1107_CR9","doi-asserted-by":"crossref","unstructured":"Wallace CA, Sherry DD. 133:266-8, s.l.: J Pediatr, 1998.","DOI":"10.1016\/S0022-3476(98)70232-X"},{"key":"1107_CR10","doi-asserted-by":"crossref","unstructured":"Ramanan AV, Dick A, Jones A, McKay A, Williamson P, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW. 376:1637\u20131646, s.l.: N Engl J Med, 2017.","DOI":"10.1056\/NEJMoa1614160"},{"key":"1107_CR11","unstructured":"Aalto K, Kotaniemi KM, Kivel\u00e4 TT, editors. Epub 2017 Nov 14, s.l.: Clin Exp Rheumatol, 2017, Vols. Nov-Dec;35(6):1043\u20131046. PMID: 29148422."},{"key":"1107_CR12","unstructured":"Liu S, Agron B, Nussenblatt E, Sen RB HN, editors. doi: 10.3109\/09273948.2013.815786. Epub 2013 Aug 19. PMID: 23957503, 2013: Ocul Immunol Inflamm, Vols. Dec;21(6):434-9. PMCID: PMC5569243."},{"key":"1107_CR13","doi-asserted-by":"publisher","unstructured":"Characterization G, Shao H, Wang Y, Kaplan HJ, Sun D. https:\/\/doi.org\/10.1167\/iovs.07-0251, s.l.: Invest Ophthalmol Vis Sci, 2007, Vols. Sep;48(9):4153-61. PMID: 17724201; PMCID: PMC2567912.","DOI":"10.1167\/iovs.07-0251"},{"key":"1107_CR14","doi-asserted-by":"crossref","unstructured":"Liu Y, Huang K GQ, editors. DOI: 10.4049\/jimmunol.0802487, (Baltimore, Md.: 1950): Journal of Immunology, 2009, Vols. Mar;182(5):3183\u20133190. PMID: 19234216; PMCID: PMC3275433.","DOI":"10.4049\/jimmunol.0802487"},{"key":"1107_CR15","doi-asserted-by":"crossref","unstructured":"Efficacy et al. and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Letko, Erik,. 10.1016\/j.ophtha.2014.12.033. Epub 2015 Jan 29., s.l.: Ophthalmology, 2015, Vols. 2015;122(5):939\u2013\u200948. doi:. PMID: 25638011.","DOI":"10.1016\/j.ophtha.2014.12.033"},{"key":"1107_CR16","first-page":"4","volume-title":"The treatment of noninfectious uveitis: results of three randomized, controlled clinical trials Dick","author":"Secukinumab","year":"2013","unstructured":"Secukinumab. the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Dick. Volume 120. s.l.: Ophthalmology; 2013. p. 4. A, Tugal-Tutkun I, Foster S, Zierhut M, Liew M, Bezlyak V, Androudi."},{"key":"1107_CR17","doi-asserted-by":"crossref","unstructured":"Secukinumab et al., an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. Baeten, Dominique,. 10.1056\/NEJMoa1505066, s.l.: N Engl J Med, 2015, Vols. 2015;373(26):2534-48. PMID: 26699169.","DOI":"10.1056\/NEJMoa1505066"},{"key":"1107_CR18","doi-asserted-by":"publisher","unstructured":"Nussenblatt DA, Robert B, Rosenbaum JT., s.l.: Am J Ophthalmol, 2005, Vols. 2005;140(3):509\u2013\u200916. PMID: 16196117; PMCID: PMC8935739. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"1107_CR19","doi-asserted-by":"crossref","unstructured":"Spiegelhalter DJ, Abrams, Keith R, Myles JP. Bayesian approaches to clinical trials and Health-Care evaluation. S.l. Wiley; 2003. Print ISBN:9780471499756|Online ISBN:9780470092606|DOI:10.1002\/0470092602.","DOI":"10.1002\/0470092602"},{"key":"1107_CR20","doi-asserted-by":"publisher","unstructured":"Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO\/CRMO. Ramanan, AV, et al. https:\/\/doi.org\/10.1371\/journal.pone.0215739, s.l.: PLoS One, 2019, Vol. 2019;14(6):e0215739. PMID: 31166977; PMCID: PMC6550371.","DOI":"10.1371\/journal.pone.0215739"},{"key":"1107_CR21","doi-asserted-by":"crossref","unstructured":"Elicitation of expert prior opinion: application to the mypan trial in childhood polyarteritis nodosa. Hampson, Lisa, et al. doi: 10.1186\/1546-0096-12-S1-P125, s.l.: Pediatr Rheumatol Online J, 2014, Vol. 2014;12(Suppl 1):P125. PMCID: PMC4190926.","DOI":"10.1186\/1546-0096-12-S1-P125"},{"key":"1107_CR22","doi-asserted-by":"publisher","unstructured":"Prior et al. elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma. Desai, Yasin, AMRC Open Res. 2021, 3:20, s.l.: Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma, 2021, Vol. version 1; peer review: 2 approved. https:\/\/doi.org\/10.12688\/amrcopenres.13008.1","DOI":"10.12688\/amrcopenres.13008.1"},{"key":"1107_CR23","unstructured":"Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, Allen J, McPherson J, Dipert A, Borges B (2025). shiny: Web Application Framework for R. R package version 1.10.0.9001, https:\/\/github.com\/rstudio\/shiny."},{"key":"1107_CR24","unstructured":"O\u2019Hagan A. The Sheffield Elicitation Framework (SHELF). [Online] [Cited: 08 May 2024.] https:\/\/shelf.sites.sheffield.ac.uk\/"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01107-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01107-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01107-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:54:32Z","timestamp":1747666472000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01107-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01107-1","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ADD is Co-Director of the National Institute of Health Research Moorfields Biomedical Research Centre, Moorfields and UCL-Institute of Ophthalmology. TJ and DSR also received funding from UK Medical Research Council (MC_UU_00002\/14 and MC_UU_00040\/03).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}